-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead Sciences Announces From Its PURPOSE 5 Study Demonstrates Higher Persistence Among Patients Starting Twice-Yearly Lenacapavir For HIV Prevention As Pre-Exposure Prophylaxis

Benzinga·11/06/2026 17:20:51
Listen to the news

Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting twice-yearly injectable lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP), compared with those starting daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). The trial included people in the United Kingdom (UK) and France who would benefit from PrEP. These data will be presented at HIV Glasgow 2026.